1. Association of prenatal exposure to endocrine-disrupting chemicals with liver injury in children
- Author
-
Vishal Midya, Elena Colicino, David V. Conti, Kiros Berhane, Erika Garcia, Nikos Stratakis, Sandra Andrusaityte, Xavier Basagaña, Maribel Casas, Serena Fossati, Regina Gražulevičienė, Line Småstuen Haug, Barbara Heude, Léa Maitre, Rosemary McEachan, Eleni Papadopoulou, Theano Roumeliotaki, Claire Philippat, Cathrine Thomsen, Jose Urquiza, Marina Vafeiadi, Nerea Varo, Miriam B. Vos, John Wright, Rob McConnell, Martine Vrijheid, Lida Chatzi, and Damaskini Valvi
- Subjects
Male ,Cohort profile ,Growth ,Endocrine Disruptors ,Phenols ,Pregnancy ,Halogenated Diphenyl Ethers ,Humans ,Prospective Studies ,Pesticides ,Nonalcoholic steatohepatitis ,Child ,Fluorocarbons ,In-utero ,Mother ,Infant, Newborn ,Bayes Theorem ,General Medicine ,National-health ,Polychlorinated Biphenyls ,Liver ,Maternal Exposure ,Metals ,Prenatal Exposure Delayed Effects ,Phthalate ,Environmental Pollutants ,Female ,Biomarkers - Abstract
Importance: Prenatal exposures to endocrine-disrupting chemicals (EDCs) may increase the risk for liver injury in children; however, human evidence is scarce, and previous studies have not considered potential EDC-mixture effects. Furthermore, the association between prenatal EDC exposure and hepatocellular apoptosis in children has not been studied previously. Objective: To investigate associations of prenatal exposure to EDC mixtures with liver injury risk and hepatocellular apoptosis in childhood. Design, setting, and participants: This prospective cohort study used data collected from April 1, 2003, to February 26, 2016, from mother-child pairs from the Human Early-Life Exposome project, a collaborative network of 6 ongoing, population-based prospective birth cohort studies from 6 European countries (France, Greece, Lithuania, Norway, Spain, and the UK). Data were analyzed from April 1, 2021, to January 31, 2022. Exposures: Three organochlorine pesticides, 5 polychlorinated biphenyls, 2 polybrominated diphenyl ethers (PBDEs), 3 phenols, 4 parabens, 10 phthalates, 4 organophosphate pesticides, 5 perfluoroalkyl substances, and 9 metals. Main outcomes and measures: Child serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), and CK-18 were measured at 6 to 11 years of age. Risk for liver injury was defined as having ALT, AST, and/or GGT levels above the 90th percentile. Associations of liver injury or cytokeratin 18 (CK-18) levels with each chemical group among the 45 EDCs measured in maternal blood or urine samples collected in pregnancy were estimated using 2 complimentary exposure-mixture methods: bayesian weighted quantile sum (BWQS) and bayesian kernel machine regression. Results: The study included 1108 mothers (mean [SD] age at birth, 31.0 [4.7] years) and their singleton children (mean [SD] age at liver assessment, 8.2 [1.6] years; 598 [54.0%] boys). Results of the BWQS method indicated increased odds of liver injury per exposure-mixture quartile increase for organochlorine pesticides (odds ratio [OR], 1.44 [95% credible interval (CrI), 1.21-1.71]), PBDEs (OR, 1.57 [95% CrI, 1.34-1.84]), perfluoroalkyl substances (OR, 1.73 [95% CrI, 1.45-2.09]), and metals (OR, 2.21 [95% CrI, 1.65-3.02]). Decreased odds of liver injury were associated with high-molecular-weight phthalates (OR, 0.74 [95% CrI, 0.60-0.91]) and phenols (OR, 0.66 [95% CrI, 0.54-0.78]). Higher CK-18 levels were associated with a 1-quartile increase in polychlorinated biphenyls (β, 5.84 [95% CrI, 1.69-10.08] IU/L) and PBDEs (β, 6.46 [95% CrI, 3.09-9.92] IU/L). Bayesian kernel machine regression showed associations in a similar direction as BWQS for all EDCs and a nonlinear association between phenols and CK-18 levels. Conclusions and relevance: With a combination of 2 state-of-the-art exposure-mixture approaches, consistent evidence suggests that prenatal exposures to EDCs are associated with higher risk for liver injury and CK-18 levels and constitute a potential risk factor for pediatric nonalcoholic fatty liver disease. This study was supported by grants R21ES029681, R01ES029944 (Dr Chatzi), R01ES030364 (Dr Chatzi), R21ES028903 (Dr Chatzi), R21ES029681 (Dr Chatzi), P30ES007048 (Dr Chatzi), R21ES029328 (Dr Valvi), R01ES029944 (Dr Valvi), R01ES028903 (Dr Valvi), P30ES023515 (Dr Valvi), and P30ES023515 (Dr Midya) from the NIEHS. The HELIX project was supported by FP7/2007-2013 under grant agreement 308333–the HELIX project from the European Community’s Seventh Framework Programme.
- Published
- 2022